Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class (Ascending) Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70518-3512-05 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 23, 2023 In Use
70518-3512-06 70518-3512 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 14, 2024 In Use
80425-0228-01 80425-0228 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 11, 2023 In Use
80425-0228-02 80425-0228 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 28, 2023 In Use
80425-0228-03 80425-0228 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 22, 2024 In Use
82650-0144-01 82650-0144 PALONOSETRON HYDROCHLORIDE Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 23, 2018 In Use
83634-0776-10 83634-0776 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 28, 2024 In Use
63187-0256-20 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 1, 2017 In Use
63187-0256-30 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 1, 2017 In Use
63187-0256-05 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-10 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-15 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-06 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 24, 2024 In Use
63187-0256-12 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 26, 2024 In Use
60687-0375-01 60687-0375 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral July 16, 2018 Sept. 30, 2025 In Use
60687-0375-21 60687-0375 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral March 31, 2024 In Use
65862-0390-10 65862-0390 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0390-19 65862-0390 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0390-30 65862-0390 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0390-05 65862-0390 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2024 In Use
65862-0391-01 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 24, 2021 In Use
65862-0391-10 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0391-30 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0391-66 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0391-02 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2024 In Use

Found 10,000 results in 8 millisecondsExport these results